INSANE: Roche | Rare Historical Photos

Lancet Publishes Full Petrelintide Trial: About 10% Weight Loss, Nausea in 20% as Amylin Drug Enters Phase 3

Full Phase 2 results for petrelintide in The Lancet show about 10% weight loss and nausea in 20%. What the experimental amylin drug means for patients.

Medical Daily · Oct 1

Roche's Enicepatide Cut Blood Sugar and Weight in Type 2 Diabetes Trial, but Placebo Figures Were Not Released

Roche says enicepatide cut HbA1c by 2.65 points and weight by 15.5% in a phase 2 diabetes trial, but placebo data were not released. Here is what the results show.

Medical Daily · Sep 23

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector

The Guardian - UK · Sep 22

Do Teenagers On Isotretinoin Actually Understand The Risks They’re Signing Off On?

For many teenagers, this acne medication is life-changing. For a small number of users, however, it brings something they never expected: depression and panic. The debate over whether patients are being warned properly has never really gone away. While most finish treatment without severe psychiatric problems, some users say the…

Bored Panda · Jul 27

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme

The Guardian - AU · Jul 16

FDA Approves First Generic Baloxavir (Xofluza): Single-Dose Flu Treatment Now Available at Generic Price

FDA approved the first generic baloxavir marboxil (Xofluza) on June 17, 2026. Norwich Pharmaceuticals developed the single-dose flu treatment for patients 5 and older.

Medical Daily · Jun 19

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times · Jun 15

Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls

The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.

Fortune · Jun 12

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat · Jun 11

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma

MarketBeat · May 15